Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

被引：0
|
作者：
McKean, M. [1 ]
Barve, M. [2 ]
Hong, D. [3 ]
Parikh, A. [4 ]
Rosen, E. [5 ]
Yang, J. [6 ]
Picard, R. [6 ]
Yi, J. [6 ]
Brail, L. [6 ]
Vecchio, D. [6 ]
Meniawy, T. [7 ]
John, T. [8 ]
Wang, J. [9 ]
机构：
[1] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[2] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[3] MD Anderson, Invest Canc Therapeut ICT, Houston, TX USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[6] Erasca Inc, San Diego, CA USA
[7] Linear Clin Res & Univ Western Australia, Med Oncol, Nedlands, WA, Australia
[8] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[9] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [31] Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study
    Frost, A.
    Buechert, M.
    Unger, C.
    Christensen, O.
    Wagner, A.
    Heinig, R. A.
    Scheulen, M. E.
    Strumberg, D.
    Fasol, U.
    Mross, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
    Mross, Klaus
    Frost, Annette
    Steinbild, Simone
    Hedbom, Susanne
    Rentschler, Jochen
    Kaiser, Rolf
    Rouyrre, Nicolas
    Trommeshauser, Dirk
    Hoesl, Cornelia E.
    Munzert, Gerd
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5511 - 5517
  • [33] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    Hollebecque, A.
    Deutsch, E.
    Massard, C.
    Gomez-Roca, C.
    Bahleda, R.
    Ribrag, V.
    Bourgier, C.
    Lazar, V.
    Lacroix, L.
    Gazzah, A.
    Varga, A.
    de Baere, T.
    Beier, F.
    Kroesser, S.
    Trang, K.
    Zenke, F. T.
    Klevesath, M.
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1530 - 1538
  • [35] Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Anne M. Traynor
    Maureen Hewitt
    Glenn Liu
    Keith T. Flaherty
    Jason Clark
    Steven J. Freedman
    Boyd B. Scott
    Ann Marie Leighton
    Patricia A. Watson
    Baiteng Zhao
    Peter J. O’Dwyer
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 305 - 314
  • [36] Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Traynor, Anne M.
    Hewitt, Maureen
    Liu, Glenn
    Flaherty, Keith T.
    Clark, Jason
    Freedman, Steven J.
    Scott, Boyd B.
    Leighton, Ann Marie
    Watson, Patricia A.
    Zhao, Baiteng
    O'Dwyer, Peter J.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 305 - 314
  • [37] A phase I single dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors.
    Mross, K
    Steinbild, S
    Frost, A
    Hedborn, S
    Rentschler, J
    Kaiser, R
    Trommeshauser, D
    Stehle, G
    Munzert, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9032S - 9032S
  • [38] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Sun, Yongkun
    Yang, Lin
    Hao, Xuezhi
    Liu, Yutao
    Zhang, Jinwen
    Ning, Zhiqiang
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [39] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [40] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey A.
    Pavlick, Anna
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58
12345